 <h1>Zerbaxa Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ceftolozane / tazobactam</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ceftolozane / tazobactam. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Zerbaxa.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ceftolozane / tazobactam: intravenous powder for solution, powder iv (infusion)</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ceftolozane / tazobactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ceftolozane / tazobactam:</p><p>
<i>More common</i>
</p><ul>
<li>Bloody urine</li>
<li>blurred vision</li>
<li>decreased frequency or amount of urine</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>increased thirst</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>swelling of the face, fingers, or lower legs</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>dry mouth</li>
<li>fainting</li>
<li>headache, sudden and severe</li>
<li>irregular heartbeat</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pale skin</li>
<li>seizures</li>
<li>skin rash</li>
<li>stomach cramps</li>
<li>sweating</li>
<li>tenderness in the stomach area</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>watery or bloody diarrhea</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Anxiety</li>
<li>bone pain</li>
<li>burning feeling in the chest or stomach</li>
<li>chest pain</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>dry, red, hot, or irritated skin</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased urination</li>
<li>indigestion</li>
<li>muscle spasms (tetany) or twitching</li>
<li>seizures</li>
<li>severe constipation</li>
<li>severe vomiting</li>
<li>stomach pain or upset</li>
<li>tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area</li>
<li>thick, white, or curd-like vaginal discharge</li>
<li>tightness in the chest</li>
<li>trembling</li>
<li>trouble thinking, speaking, or walking</li>
<li>unexplained weight loss</li>
<li>white patches in the mouth or throat or on the tongue</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ceftolozane / tazobactam may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Belching</li>
<li>bloated or full feeling</li>
<li>excess air or gas in the stomach or bowels</li>
<li>heartburn</li>
<li>passing gas</li>
</ul><p>
<!-- end intravenous powder for solution, powder iv (infusion) --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftolozane / tazobactam: intravenous powder for injection</i></p><h3>General</h3><p>In clinical studies of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI), the most common side effects were nausea, diarrhea, headache, constipation, and pyrexia.</p>
<p></p>
<p>In a clinical study for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP), side effects reported in at least 2% of patients included increased hepatic transaminase, renal impairment/renal failure, diarrhea, intracranial hemorrhage, vomiting, and Clostridioides difficile colitis; the most common side effects were diarrhea, increased ALT, and increased AST.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Positive direct Coombs test (up to 31.2%)</p>
<p><b>Common</b> (1% to 10%): Anemia, thrombocytosis<sup>[Ref]</sup></p><p>In cIAI and cUTI clinical studies, seroconversion to positive direct Coombs test was reported in 0.2% of patients using this drug (0% in patients using the comparator).  In the HABP/VABP clinical study, seroconversion to positive direct Coombs test was reported in 31.2% of patients using this drug (3.6% in patients using meropenem).  In clinical studies, hemolysis was not reported in patients who developed a positive direct Coombs test (in any treatment group).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased hepatic transaminase (up to 11.9%; included increased ALT, increased AST, increased hepatic enzyme, hypertransaminasemia, abnormal liver function test)</p>
<p><b>Common</b> (1% to 10%): Increased ALT, increased AST, increased transaminases, abnormal liver function test, increased serum GGT<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment/renal failure (included acute renal failure, anuria, azotemia, oliguria, prerenal failure, renal failure, renal impairment)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, constipation, vomiting, abdominal pain, C difficile colitis (included C difficile colitis, C difficile infection, Clostridioides test positive)</p>
<p><b>Uncommon</b> (0.1% to 1%): Paralytic ileus, gastritis, abdominal distension, dyspepsia, flatulence, oropharyngeal candidiasis</p>
<p><b>Frequency not reported</b>: C difficile-associated diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, intracranial hemorrhage (included cerebellar hemorrhage, cerebral hematoma, cerebral hemorrhage, intracranial hemorrhage, hemorrhagic stroke, hemorrhagic transformation stroke intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma)</p>
<p><b>Uncommon</b> (0.1% to 1%): Ischemic stroke<sup>[Ref]</sup></p><h3>Other</h3><p>In phase 2 and 3 cIAI trials, death occurred in 14 of 564 patients using this drug and 8 of 536 patients using meropenem; causes of death varied and included worsening and/or complications of infection, surgery, and underlying conditions.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia, increased mortality, increased serum alkaline phosphatase</p>
<p><b>Uncommon</b> (0.1% to 1%): Candidiasis, C difficile infection, Clostridioides test positive<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1 to 10%): Insomnia, anxiety<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia, hypomagnesemia, hypophosphatemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, atrial fibrillation</p>
<p><b>Uncommon</b> (0.1% to 1%): Tachycardia, angina pectoris, venous thrombosis, phlebitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p></p>
<p>Beta-lactam antibiotics:</p>
<p>-Frequency not reported: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Vulvovaginal candidiasis, fungal urinary tract infection</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Zerbaxa (ceftolozane-tazobactam)." Cubist Pharmaceuticals Inc, Lexington, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Zerbaxa (ceftolozane / tazobactam)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: cephalosporins/beta-lactamase inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zerbaxa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Intraabdominal Infection</li>
<li>Pneumonia</li>
<li>Urinary Tract Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftolozane / tazobactam: intravenous powder for injection</i></p><h3>General</h3><p>In clinical studies of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI), the most common side effects were nausea, diarrhea, headache, constipation, and pyrexia.</p><p></p><p>In a clinical study for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP), side effects reported in at least 2% of patients included increased hepatic transaminase, renal impairment/renal failure, diarrhea, intracranial hemorrhage, vomiting, and Clostridioides difficile colitis; the most common side effects were diarrhea, increased ALT, and increased AST.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Positive direct Coombs test (up to 31.2%)</p><p><b>Common</b> (1% to 10%): Anemia, thrombocytosis<sup>[Ref]</sup></p><p>In cIAI and cUTI clinical studies, seroconversion to positive direct Coombs test was reported in 0.2% of patients using this drug (0% in patients using the comparator).  In the HABP/VABP clinical study, seroconversion to positive direct Coombs test was reported in 31.2% of patients using this drug (3.6% in patients using meropenem).  In clinical studies, hemolysis was not reported in patients who developed a positive direct Coombs test (in any treatment group).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased hepatic transaminase (up to 11.9%; included increased ALT, increased AST, increased hepatic enzyme, hypertransaminasemia, abnormal liver function test)</p><p><b>Common</b> (1% to 10%): Increased ALT, increased AST, increased transaminases, abnormal liver function test, increased serum GGT<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment/renal failure (included acute renal failure, anuria, azotemia, oliguria, prerenal failure, renal failure, renal impairment)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, constipation, vomiting, abdominal pain, C difficile colitis (included C difficile colitis, C difficile infection, Clostridioides test positive)</p><p><b>Uncommon</b> (0.1% to 1%): Paralytic ileus, gastritis, abdominal distension, dyspepsia, flatulence, oropharyngeal candidiasis</p><p><b>Frequency not reported</b>: C difficile-associated diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, intracranial hemorrhage (included cerebellar hemorrhage, cerebral hematoma, cerebral hemorrhage, intracranial hemorrhage, hemorrhagic stroke, hemorrhagic transformation stroke intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma)</p><p><b>Uncommon</b> (0.1% to 1%): Ischemic stroke<sup>[Ref]</sup></p><h3>Other</h3><p>In phase 2 and 3 cIAI trials, death occurred in 14 of 564 patients using this drug and 8 of 536 patients using meropenem; causes of death varied and included worsening and/or complications of infection, surgery, and underlying conditions.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia, increased mortality, increased serum alkaline phosphatase</p><p><b>Uncommon</b> (0.1% to 1%): Candidiasis, C difficile infection, Clostridioides test positive<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1 to 10%): Insomnia, anxiety<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p><p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia, hypomagnesemia, hypophosphatemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, atrial fibrillation</p><p><b>Uncommon</b> (0.1% to 1%): Tachycardia, angina pectoris, venous thrombosis, phlebitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p></p><p>Beta-lactam antibiotics:</p><p>-Frequency not reported: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Vulvovaginal candidiasis, fungal urinary tract infection</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Zerbaxa (ceftolozane-tazobactam)." Cubist Pharmaceuticals Inc, Lexington, MA. </p><h2>More about Zerbaxa (ceftolozane / tazobactam)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: cephalosporins/beta-lactamase inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zerbaxa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Intraabdominal Infection</li>
<li>Pneumonia</li>
<li>Urinary Tract Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>